L Lattenist1, P Ochodnický1, M Ahdi2, N Claessen1, J C Leemans1, S C Satchell3, S Florquin1,4, V E Gerdes2,5, J J T H Roelofs1. 1. Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands. 3. Academic Renal Unit, University of Bristol, Bristol, UK. 4. Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. 5. Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
UNLABELLED: Essentials Endothelial protein C receptor (EPCR) promotes diabetic nephropathy (DN) outcome improvement. Renal expression and shedding of EPCR were measured in diabetic patients with or without DN. Inhibition of metalloproteinase-driven EPCR shedding restored glomerular endothelium phenotype. EPCR shedding through metalloproteinase ADAM17 contributes to the worsening of DN. SUMMARY: Background Diabetic nephropathy (DN) represents the leading cause of end-stage renal disease. The endothelial protein C receptor (EPCR) and its ligand (activated protein C) have been shown to ameliorate the phenotype of DN in mice. EPCR activity can be regulated by proteolytic cleavage involving ADAMs, yielding a soluble form of EPCR (sEPCR). Objective To characterize the renal expression and shedding of EPCR during DN. Methods EPCR levels were measured in plasma, urine and biopsy samples of diabetic patients with (n = 73) or without (n = 63) DN. ADAM-induced cleavage of EPCR was investigated in vitro with a human glomerular endothelium cell line. Results DN patients showed higher plasma and urinary levels of sEPCR than diabetic controls (112.2 versus 135.2 ng mL(-1) and 94.35 versus 140.6 ng mL(-1) , respectively). Accordingly, glomerular endothelial EPCR expression was markedly reduced in patients with DN, and this was associated with increased glomerular expression of ADAM-17 and ADAM-10. In vitro, EPCR shedding was induced by incubation of glomerular endothelium in high-glucose medium, and this shedding was suppressed by ADAM-17 inhibition or silencing, which led to improved vascular endothelial cadherin (VE-cadherin) expression and reduced mRNA expression of transforming growth factor (TGF)-β. In addition, EPCR silencing led to minor effects on VE-cadherin but to a significant increase in TGF-β mRNA expression. Conclusion Inhibition of ADAM-driven glomerular EPCR shedding restored the endothelial phenotype of glomerular endothelium, whereas EPCR silencing led to enhanced expression of TGF-β, a marker of endothelial-mesenchymal transition. These findings demonstrate that EPCR shedding driven by ADAMs contributes to the worsening of DN.
UNLABELLED: Essentials Endothelial protein C receptor (EPCR) promotes diabetic nephropathy (DN) outcome improvement. Renal expression and shedding of EPCR were measured in diabeticpatients with or without DN. Inhibition of metalloproteinase-driven EPCR shedding restored glomerular endothelium phenotype. EPCR shedding through metalloproteinase ADAM17 contributes to the worsening of DN. SUMMARY: Background Diabetic nephropathy (DN) represents the leading cause of end-stage renal disease. The endothelial protein C receptor (EPCR) and its ligand (activated protein C) have been shown to ameliorate the phenotype of DN in mice. EPCR activity can be regulated by proteolytic cleavage involving ADAMs, yielding a soluble form of EPCR (sEPCR). Objective To characterize the renal expression and shedding of EPCR during DN. Methods EPCR levels were measured in plasma, urine and biopsy samples of diabeticpatients with (n = 73) or without (n = 63) DN. ADAM-induced cleavage of EPCR was investigated in vitro with a human glomerular endothelium cell line. Results DN patients showed higher plasma and urinary levels of sEPCR than diabetic controls (112.2 versus 135.2 ng mL(-1) and 94.35 versus 140.6 ng mL(-1) , respectively). Accordingly, glomerular endothelial EPCR expression was markedly reduced in patients with DN, and this was associated with increased glomerular expression of ADAM-17 and ADAM-10. In vitro, EPCR shedding was induced by incubation of glomerular endothelium in high-glucose medium, and this shedding was suppressed by ADAM-17 inhibition or silencing, which led to improved vascular endothelial cadherin (VE-cadherin) expression and reduced mRNA expression of transforming growth factor (TGF)-β. In addition, EPCR silencing led to minor effects on VE-cadherin but to a significant increase in TGF-β mRNA expression. Conclusion Inhibition of ADAM-driven glomerular EPCR shedding restored the endothelial phenotype of glomerular endothelium, whereas EPCR silencing led to enhanced expression of TGF-β, a marker of endothelial-mesenchymal transition. These findings demonstrate that EPCR shedding driven by ADAMs contributes to the worsening of DN.
Authors: D Szukiewicz; Grzegorz Szewczyk; Michal Pyzlak; Aleksandra Stangret; Michal Bachanek; Seweryn Trojanowski; Habib Alkhalayla; Jaroslaw Wejman Journal: Inflammation Date: 2018-12 Impact factor: 4.092
Authors: Xiaoping Qing; Yurii Chinenov; Patricia Redecha; Michael Madaio; Joris Jth Roelofs; Gregory Farber; Priya D Issuree; Laura Donlin; David R Mcllwain; Tak W Mak; Carl P Blobel; Jane E Salmon Journal: J Clin Invest Date: 2018-03-05 Impact factor: 14.808
Authors: Dariusz Szukiewicz; Michal Pyzlak; Grzegorz Szewczyk; Aleksandra Stangret; Seweryn Trojanowski; Michal Bachanek; Wojciech Braksator; Jaroslaw Wejman Journal: Mediators Inflamm Date: 2017-06-01 Impact factor: 4.711
Authors: Melissa Uil; Chi M Hau; Mohamed Ahdi; James D Mills; Jesper Kers; Moin A Saleem; Sandrine Florquin; Victor E A Gerdes; Rienk Nieuwland; Joris J T H Roelofs Journal: Clin Kidney J Date: 2019-10-23
Authors: Vanesa Palau; Josué Jarrín; Sofia Villanueva; David Benito; Eva Márquez; Eva Rodríguez; María José Soler; Anna Oliveras; Javier Gimeno; Laia Sans; Marta Crespo; Julio Pascual; Clara Barrios; Marta Riera Journal: Int J Mol Sci Date: 2021-12-25 Impact factor: 5.923
Authors: Nicholas J Carruthers; Clarissa Strieder-Barboza; Joseph A Caruso; Carmen G Flesher; Nicki A Baker; Samuel A Kerk; Alexander Ky; Anne P Ehlers; Oliver A Varban; Costas A Lyssiotis; Carey N Lumeng; Paul M Stemmer; Robert W O'Rourke Journal: Sci Rep Date: 2021-08-30 Impact factor: 4.379
Authors: Vanesa Palau; Bramasta Nugraha; David Benito; Julio Pascual; Maximilian Y Emmert; Simon P Hoerstrup; Marta Riera; Maria José Soler Journal: Int J Mol Sci Date: 2021-05-24 Impact factor: 5.923